New drug combo aims to stall advanced prostate cancer
NCT ID NCT03787680
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of two drugs, olaparib and AZD6738, can shrink tumors or lower PSA levels in men with advanced prostate cancer that no longer responds to hormone therapy. About 49 men with metastatic castration-resistant prostate cancer will receive the drug combo. The goal is to see if the treatment can control the disease, especially in men whose tumors have certain DNA repair features.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan Hospital
Ann Arbor, Michigan, 48109, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new pill outsmart resistant prostate cancer?
- A second look: MRI screening may spot hidden prostate cancers
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?